All In Biotech

Drug Trial Radar · NCT06764875

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

840

Planned (sponsor's estimate)

Start

Mar 1, 2025

Primary completion

Apr 27, 2029

Study completion Dec 9, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

Conditions

  • HER2-positive Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Interventions

  • RilvegostomigDrug

    Q3W, intravenous infusion

  • Trastuzumab deruxtecanDrug

    Q3W, intravenous infusion

  • TrastuzumabDrug

    Q3W, intravenous infusion

  • PembrolizumabDrug

    Q3W, intravenous infusion

  • 5-fluorouracilDrug

    Q3W, intravenous infusion

  • CapecitabineDrug

    BID, oral administration

  • CisplatinDrug

    Q3W, intravenous infusion

  • OxaliplatinDrug

    Q3W, intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: Up to approximately 6 years
  2. Overall Survival (OS)Time frame: Up to approximately 6 years

Locations

304 sites in 28 countries. Site status is shown where the registry gives one.

  • Research Site

    Anchorage, Alaska · Recruiting

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Los Alamitos, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Santa Monica, California · Recruiting

  • Research Site

    Solvang, California · Recruiting

  • Research Site

    Upland, California · Recruiting

  • Research Site

    Walnut Creek, California · Recruiting

  • Research Site

    Aurora, Colorado · Recruiting

  • Research Site

    Newark, Delaware · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Orlando, Florida · Recruiting

  • Research Site

    Athens, Georgia · Withdrawn

  • Research Site

    Marietta, Georgia · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Chicago, Illinois · Withdrawn

  • Research Site

    Evanston, Illinois · Recruiting

  • Research Site

    Hinsdale, Illinois · Recruiting

  • Research Site

    Niles, Illinois · Recruiting

  • Research Site

    Dyer, Indiana · Withdrawn

  • Research Site

    Waukee, Iowa · Not yet recruiting

  • Research Site

    Lexington, Kentucky · Not yet recruiting

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    Silver Spring, Maryland · Recruiting

  • Research Site

    Boston, Massachusetts · Withdrawn

  • Research Site

    Boston, Massachusetts · Withdrawn

  • Research Site

    Worcester, Massachusetts · Withdrawn

  • Research Site

    Detroit, Michigan · Recruiting

  • Research Site

    Grand Rapids, Michigan · Recruiting

  • Research Site

    Burnsville, Minnesota · Withdrawn

  • Research Site

    Kansas City, Missouri · Withdrawn

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Omaha, Nebraska · Recruiting

  • Research Site

    Reno, Nevada · Recruiting

  • Research Site

    Summit, New Jersey · Recruiting

  • Research Site

    Santa Fe, New Mexico · Recruiting

Showing 40 of 304 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.